Should you buy, sell or hold PNB, NTPC, PowerGrid, Zomato, JSW Steel shares?

Which stocks to buy, hold or sell today? As Dalal Street enters the May 22 session, here's a look at what brokerages make of some of the key stocks in focus. On their radar are stocks such as Punjab National Bank, Zomato, PowerGrid, NTPC and JSW Steel.

Here's what brokerages make of some of the top stocks in focus today. | Image: Pixabay

Which stocks to buy, hold or sell today? As Dalal Street enters the May 22 session, here's a look at what brokerages make of some of the key stocks in focus. On their radar are scrips such as Punjab National Bank (PNB), JSW Steel, PowerGrid, NTPC and Zomato.

Do you have any of these stocks in your portfolio?

PNB shares

Brokerage	Rating	Target price
Morgan Stanley	Underweight	Rs 55
JPMorgan	Overweight	Rs 72
Citi	Sell	Raised to Rs 42 from Rs 41
Jefferies	Hold	Rs 54

PowerGrid shares

CLSA maintained an 'outperform' rating on PowerGrid but reduced its target price by Rs 4 to Rs 255.

Morgan Stanley continued with 'overweight' with a target of Rs 258.

Zomato shares

Brokerage	Rating	Target price
CLSA	Buy	Raised to Rs 80 from Rs 70
Morgan Stanley	Overweight	Raised to Rs 85 from Rs 74
JPMorgan	Overweight	Reduced to Rs 90 from Rs 100
Citi	Buy	Raised to RS 84 from Rs 76
Jefferies	Buy	Rs 100
Goldman Sachs	Buy	Raised to Rs 82 from Rs 80
Nomura	Reduce	Rs 45
HSBC	Buy	Raised to Rs 88 from Rs 87
Credit Suisse	Outperform	Rs 82

According to Goldman Sachs, Zomato's Q4 results and latest management commentary were better than its expectations, on the back of improving growth and profit outlook.

JSW Steel shares

Brokerage	Rating	Target price
CLSA	sell	Raised to Rs 655 from Rs 640
Morgan Stanley	Underweight	Rs 580
Jefferies	Underperform	Raised to Rs 510 from Rs 470
Citi	Sell	Reduced to Rs 600 from Rs 675
Nomura	Reduce	Raised to Rs 605 from Rs 570

NTPC shares

CLSA retained a 'buy' call on NTPC with a target price of Rs 209.

Morgan Stanley continued with 'overweight' with a target of Rs 198.

Divi's Labs shares

According to Jefferies, which upgraded Divi's Laboratories to 'buy' from 'underperform', believes the drug maker should in on track to achieving revenue growth in mid or high teens from the quarter ending September 2023. The brokerage raised its target price for the pharma company's stock to Rs 3,610 from Rs 2,550.

Divi's Labs' revenue and EBITDA for the quarter ended March 2023 was ahead of the brokerage's estimates.

Goldman Sachs maintained a 'buy' rating on Divi's but reduced its target to Rs 3,400 from Rs 3,500.

Bandhan Bank

Brokerage	Rating	Target price
CLSA	Buy	Rs 320
Jefferies	Buy	Rs 340
Goldman Sachs	Buy	Raised to Rs 294 from Rs 269
Nomura	Buy	Reduced to Rs 310 from Rs 320